• Explore /
  • Poster
  • / Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach.

Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach.

Abstract Poster

Authors

Rujul H Parikh

Rujul H Parikh

Emory University, Winship Cancer Institute, Atlanta, GA

Rujul H Parikh , Craig C. Hofmeister , Dhwani Almaula , Leonard T. Heffner , Vikas Anand Gupta , Lawrence Boise , Jonathan L. Kaufman , Madhav V. Dhodapkar , Sagar Lonial , Ajay K. Nooka , Nisha Joseph

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8061)

DOI

10.1200/JCO.2022.40.16_suppl.8061

Abstract #

8061

Poster Bd #

484

Abstract Disclosures

Similar Posters

First Author: Robert M. Rifkin

First Author: Ajay K. Nooka

First Author: E. Bridget Kim

First Author: Shaji Kumar